Stanford Cancer Institute Palo Alto
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States122 results ยท Page 1 of 5
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07198074 | |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2026-10-09 | NCT06029270 | |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7 | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05987241 | |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-09 | NCT04269902 | |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-09 | NCT04181060 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, uterine disorder | Recruiting | Phase 2 | 2026-10-08 | NCT05564377 | |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT04628767 | |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT04267848 | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-10-08 | NCT03678025 | |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, histiocytoma, liposarcoma, neoplasm, sarcoma, undifferentiated pleomorphic sarcoma | Recruiting | Phase 3 | 2026-10-07 | NCT06422806 | |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 | 2026-10-07 | NCT03739814 | |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-10-06 | NCT07195734 | |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-10-06 | NCT04533750 | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-10-06 | NCT01841736 | |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | Abdominal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Peritoneal Diseases, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, neoplasm, peritoneal neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07001748 | |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | CNS demyelinating autoimmune disease, Crohn disease, Digestive System Diseases, Hemic and Lymphatic Diseases, Neoplasms by Site, Sjogren syndrome, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, autoimmune disorder of the nervous system, bone disorder, colitis, colonic disorder, connective tissue disorder, demyelinating disease, dermatomyositis, digestive system disorder, dry eye syndrome, eye disorder, gastroenteritis, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, immune system disorder, inflammatory bowel disease, intestinal disorder, lacrimal apparatus disorder, mouth disorder, multiple sclerosis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, neoplasm, nervous system disorder, neuromuscular disease, polymyositis, psoriasis, psoriatic arthritis, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, spondylitis, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, vertebral column disorder | Recruiting | Phase 1 | 2026-10-05 | NCT03816345 | |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2+ Breast Cancer | Recruiting | Phase 3 | 2026-10-02 | NCT06876714 | |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma of the corpus uteri, endometrial carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05256225 | |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, central nervous system cancer, grade II meningioma, intracranial meningioma, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Active, not recruiting | Phase 3 | 2026-10-02 | NCT03180268 | |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 3 | 2026-10-02 | NCT03150693 | |
| Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pancreas disorder, pancreatic endocrine carcinoma, pancreatic neoplasm, primitive neuroectodermal tumor, somatostatinoma | Active, not recruiting | Phase 2 | 2026-10-02 | NCT02595424 | |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, lymphoid interstitial pneumonia, mouth disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT05063552 | |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, immune system disorder, immunoproliferative disorder, intravascular large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, neoplasm, primary cutaneous diffuse large B-cell lymphoma, Leg type | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT04799275 | |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03907488 | |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03701282 |